• Explore /
  • Poster
  • / A phase 2 study of the MDM2 inhibitor milademetan in patients with <em>TP53</em>-wild type and <em>MDM2</em>-amplified advanced or metastatic solid tumors (MANTRA-2).

A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2).

Abstract Poster

Authors

Ecaterina Dumbrava

Ecaterina Elena Dumbrava

The University of Texas MD Anderson Cancer Center, Houston, TX

Ecaterina Elena Dumbrava , Glenn J. Hanna , Gregory Michael Cote , Tom Stinchcombe , Melissa Lynne Johnson , Christopher Chen , Siddhartha Devarakonda , Naisargee Shah , Feng Xu , Robert Charles Doebele , Mrinal M. Gounder

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Clinical Trial Registration Number

NCT05012397

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS3165)

DOI

10.1200/JCO.2022.40.16_suppl.TPS3165

Abstract #

TPS3165

Poster Bd #

149b

Abstract Disclosures

Similar Posters

First Author: Anthony W. Tolcher

First Author: Curtis Robert Chong

First Author: Takafumi Koyama

First Author: Taofeek K. Owonikoko